Elicio Q3 Loss Narrows to $8.0M; Cash Runway Extended to Q2 2027
ELTX is trading near its 52-week low of $1.4 (0.4% above the low).
Summary
Elicio reported a narrower Q3 2026 net loss of $8.0 million and $30.9 million in cash, extending runway into Q2 2027, while new AMPLIFY-7P subgroup data support a targeted Phase 3 strategy in adjuvant pancreatic cancer.
Key Events · Earnings and Guidance · ELTX
-
Q3 Loss Narrows to $8.0M
Net loss for Q3 2026 was $8.0 million, or $0.30 per share, versus $10.1 million, or $0.60 per share, in Q3 2025. R&D fell to $4.9 million from $5.0 million, while G&A rose to $3.6 million from $3.0 million.
-
Cash Runway Extended to Q2 2027
Cash and cash equivalents stood at $30.9 million as of September 30, 2026, which the company expects to support operations into the second quarter of 2027.
-
New AMPLIFY-7P Subgroup Analyses
Pre-specified analyses showed a 49% reduction in risk of recurrence or death in ctDNA-negative patients, 43% in ctDNA-positive patients and 41% in patients without prior radiation; a multivariable analysis estimated HR 0.47 (p=0.0086). The trial still missed its primary DFS endpoint in the intent-to-treat population.
-
Phase 1 Combination Study Targeted Q4 2026
Elicio is targeting a Q4 2026 start for a Phase 1 study of camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC.
Analysis · ELTX · Life Sciences
Elicio's Q3 net loss narrowed to $8.0 million from $10.1 million a year ago, and with $30.9 million in cash the company now funds operations into the second quarter of 2027—roughly a quarter longer than the prior Q1 2027 guidance. That buys time, but going-concern doubt previously disclosed in the 10-K still hangs over the story, and the company must keep funding a Phase 3 adjuvant PDAC plan after the AMPLIFY-7P trial missed its primary endpoint on October 23. New subgroup analyses—a 49% reduction in recurrence or death risk in ctDNA-negative patients and a 43% reduction in ctDNA-positive patients—underpin a narrower, biomarker-targeted Phase 3 strategy rather than a broad one. A Phase 1 combination study with daraxonrasib is targeted for Q4 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTX was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.9M. The 52-week trading range was $1.40 to $16.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.